Xeris Biopharma Holdings Inc (XERS)
EBITDA Growth
124.39%
TTM · Period ending:
XERS EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported124.39%period ending
Latest reported124.39%period ending
XERS TTM EBITDA YoY % (-116.82% → 124.39%)
Year-over-year change
High-resolution chart · PNG
XERS ebitda growth history
Trailing twelve months (TTM). Each value covers four complete reported quarters.
| Period ending | EBITDA Growth |
|---|---|
| 124.3879% | |
| 1,163.0791% | |
| 350.3001% | |
| 215.421% | |
| 142.8903% | |
| 82.451% | |
| 41.0407% | |
| 10.5414% | |
| 55.311% | |
| 48.4455% | |
| 65.1422% | |
| 76.7267% | |
| 67.7408% | |
| 61.6181% | |
| 40.0955% | |
| -34.4661% | |
| -66.545% | |
| -83.6422% | |
| -43.6573% | |
| 12.2865% | |
| 34.5161% | |
| 43.8059% | |
| 32.8311% | |
| 10.8449% | |
| -21.2848% | |
| -73.8635% | |
| -105.8848% | |
| -123.6141% | |
| -122.5826% | |
| -108.3219% | |
| -116.822% |